Skip to main content
Fig. 4 | Microbiome

Fig. 4

From: IL-22 alters gut microbiota composition and function to increase aryl hydrocarbon receptor activity in mice and humans

Fig. 4

Efmarodocokin alfa administration increases fecal AhR activity in humans. A Fecal concentrations of L-Trp, I3C, and IPA at screening in HV (n=69) compared to UC (n=46). P value determined by rank-sum test. B AUC of Log2(fold change from screening) for fecal AhR activity in enrolled UC patients following administration of efmarodocokin alfa (n=8) or placebo (n=5). C Scatterplot of fecal AhR activity vs. fecal concentrations of I3C and IPA at screening only (n=23) and at all visits (n=104) in enrolled UC patients. Spearman’s rank correlation coefficient (rho) was calculated to determine correlation strength. D Mean AUC of Log2(fold change from screening) for normalized abundance of IL-22Fc-depleted (n=7) or -enriched (n=5) genera detected in enrolled UC patients receiving efmarodocokin alfa treatment. E Mean ΔAUC (AUC in efmarodocokin alfa-treated UC patients—AUC in placebo-treated UC patients) of IL-22Fc-depleted (n=7) or -enriched (n=5) genera detected in enrolled UC patients. For panels B, D, and E, only enrolled UC patients with a complete sample collection history (screening, day 29, day 43, day 64, and day 85) were considered for AUC calculations. P value determined by Student’s T test

Back to article page